DisperSol Technologies

7 articles with DisperSol Technologies

• DisperSol and Catalent Collaborate to Establish KinetiSol® Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline

  8/2/2021

  DisperSol Technologies and Catalent announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.

• DisperSol Technologies Promotes Dave Miller to Chief Scientific Officer

  7/14/2021

  DisperSol Technologies LLC announced that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.

• DisperSol Technologies Promotes Chris Brough to Chief Technology Officer

  7/14/2021

  DisperSol Technologies LLC announced that it is promoting Chris Brough from Vice President Technology to Chief Technology Officer effective immediately.

• DisperSol Technologies Names David Snyder as Chief Financial Officer

  9/24/2020

  DisperSol Technologies LLC announced today that its Board of Directors has appointed David S. Snyder as its Chief Financial Officer effective October 1, 2020. “David Snyder is a highly accomplished pharmaceutical finance executive with extensive experience in managing the finances and growth of life science businesses,” said Dr. Edwar

• DisperSol Technologies Raising $27 Million and Initiating Phase II Trials of DST-0509 in Iron Overload Disorder

  4/26/2018

  DisperSol Technologies, LLC, has secured commitments for $27 million in equity financing.

• DisperSol Technologies Announces New R&D Data to Be Presented at 2017 Annual Meeting of AAPS  

  11/9/2017

  The symposium will highlight partners' experiences with KinetiSol: a novel manufacturing technology for making amorphous solid dispersions of poorly water-soluble drug molecules to enhance their bioavailability & clinical effectiveness.

• DisperSol Names Dr. Edward M. Rudnic As Chief Executive Officer, RCT Leads $12 Million Funding Round

  11/9/2016